Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Zacks News
Agios (AGIO) Secures FDA Approval for Leukemia Drug Tibsovo
by Zacks Equity Research
Agios (AGIO) gains an FDA approval for its lead pipeline candidate, Tibsovo, for the treatment of relapsed/refractory acute myeloid leukemia (AML) in patients with an IDH1 mutation.
Here's Why You Should Add Abbott (ABT) to Your Portfolio Now
by Zacks Equity Research
We are upbeat about Abbott's (ABT) synergies from Alere buyout in the form of solid Rapid Diagnostics revenues. Emerging market performance has been promising.
The Zacks Analyst Blog Highlights: Wells Fargo, IBM, Abbott, Texas Instruments and Praxair
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Wells Fargo, IBM, Abbott, Texas Instruments and Praxair
Can Solid Global Prospects Drive Align's (ALGN) Q2 Earnings?
by Zacks Equity Research
Align Technology (ALGN) poised to gain on continued strength in all geographies in Q2.
Top Stock Reports for Wells Fargo, IBM & Abbott
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo (WFC), IBM (IBM) and Abbott (ABT).
Abbott (ABT) Q2 Earnings & Revenues Top Estimates, View Up
by Zacks Equity Research
Abbott (ABT) posts another quarter of strong EPD and Medical Devices performance. Particularly, Abbott has been riding high on a healthy growth within its Diabetes Care business.
Housing Starts/Permits Disappoint; MS, USB and ABT Beat
by Mark Vickery
Morgan Stanley, U.S. Bank and Abbott all beat expectations, but new Housing Starts and Permits numbers were far below expectations.
Abbott (ABT) Beats on Earnings and Revenues in Q2
by Zacks Equity Research
Abbott (ABT) gains ground on new product launches and solid overall growth and delivers strong Q2 results.
These Companies are Earnings All-Stars
by Tracey Ryniec
It's not easy to beat on earnings nearly every quarter but these 5 companies are doing just that. Can they keep up their winning streaks?
Can Established Pharmaceuticals Up Abbott (ABT) Q2 Earnings?
by Zacks Equity Research
According to Abbott (ABT), key emerging markets represent the most attractive long-term growth opportunities for its branded generics product portfolio within EPD.
Can Medical Devices Strength Drive Abbott (ABT) Q2 Earnings?
by Zacks Equity Research
Abbott (ABT) poised to gain on continued growth in Medical Devices business in Q2.
Can Abbott (ABT) Rise on Robust Overall Growth in Q2 Earnings?
by Zacks Equity Research
Abbott (ABT) gains traction from a steady healthy growth trajectory seen in core Diabetes Care business.
Here's Why AbbVie Stock is Good for Your Portfolio's Health
by Zacks Equity Research
Here are six reasons why investing in AbbVie (ABBV) stock is a good decision now.
The Zacks Analyst Blog Highlights: Facebook, Amgen, Abbott, Coca-Cola and 3M
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, Amgen, Abbott, Coca-Cola and 3M
Top Stock Reports for Facebook, Amgen & Abbott
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Amgen (AMGN), and Abbott (ABT).
Tap Cardiovascular Devices Market Boom With These 3 Stocks
by Sweta Jaiswal
Consider these three stocks in the rapidly-growing cardiovascular devices market.
Zacks Industry Outlook Highlights: Boston Scientific, Stryker, Medtronic, Abbott and Varian Medical
by Zacks Equity Research
Zacks Industry Outlook Highlights: Boston Scientific, Stryker, Medtronic, Abbott and Varian Medical
Boston Scientific Up on Possible Takeover Bid by Stryker
by Zacks Equity Research
Even if Boston Scientific's (BSX) position remains indefinite on a possible sell-off rumor, the company's strategic stance on this might however, swing in its favor for winning a competitive marketing edge.
Bio-Rad Banks on Solid Global Scenario, Competition Rife
by Zacks Equity Research
Bio-Rad (BIO) delivers robust performance, primarily in North America, China and the Asia-Pacific region.
Abbott Launches Afinion 2 Analyzer Rapid Test in the U.S.
by Zacks Equity Research
Abbott's (ABT) recently-launched Afinion 2 analyzer system is likely to boost top-line contributions from the Diagnostic division.
The Zacks Analyst Blog Highlights: Duke, Charter Communications, Abbott, UnitedHealth and Brown-Forman
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Duke, Charter Communications, Abbott, UnitedHealth and Brown-Forman
Abbott Presents Positive Data for AMPLATZER Amulet Device
by Zacks Equity Research
Abbott (ABT) proceeds with initiatives to boost the core Structural Heart division.
Abbott Presents Positive Study Results for Tendyne Device
by Zacks Equity Research
Abbott (ABT) leaves no stone unturned to drive its Structural Heart business.
Abbott Gets FDA Nod for XIENCE Sierra, To Boost Vascular Wing
by Zacks Equity Research
Abbott (ABT) continues with the slew of developments in regards with the XIENCE Sierra coronary stent system.
Cardiovascular Systems Rides on New Products Amid Tight Race
by Zacks Equity Research
Cardiovascular Systems (CSII) gains traction from a strong third-quarter fiscal 2018, witnessing a year-over-year revenue rise at both CAD and PAD businesses.